-
Australia's Cummins, Lyon out of fourth Ashes Test
-
US singer Barry Manilow reveals lung cancer diagnosis
-
'Call of Duty' co-creator Vince Zampella killed in car crash
-
Trump says would be 'smart' for Venezuela's Maduro to step down
-
Steelers' Metcalf suspended two games over fan outburst
-
Salah, Foster take Egypt and South Africa to AFCON Group B summit
-
Napoli beat Bologna to lift Italian Super Cup
-
Salah snatches added-time winner for Egypt after Zimbabwe scare
-
Penalty king Jimenez strikes for Fulham to sink Forest
-
Kansas City Chiefs confirm stadium move
-
Liverpool rocked by Isak blow after surgery on ankle injury
-
US stocks push higher while gold, silver notch fresh records
-
Deadly clashes in Aleppo as Turkey urges Kurds not to be obstacle to Syria's stability
-
Is the United States after Venezuela's oil?
-
Trump admin halts US offshore wind projects citing 'national security'
-
Right wing urges boycott of iconic Brazilian flip-flops
-
From misfits to MAGA: Nicki Minaj's political whiplash
-
Foster grabs South Africa winner against Angola in AFCON
-
Russia pledges 'full support' for Venezuela against US 'hostilities'
-
Spotify says piracy activists hacked its music catalogue
-
Winter Olympics organisers resolve snow problem at ski site
-
Fuming Denmark summons US ambassador over Greenland envoy
-
UK's street artist Banksy unveils latest mural in London
-
Rugby players lose order challenge in brain injury claim
-
UK singer Chris Rea dies at 74, days before Christmas
-
Last of kidnapped Nigerian pupils handed over, government says
-
Zambia strike late to hold Mali in AFCON opener
-
Outcry follows CBS pulling program on prison key to Trump deportations
-
Sri Lanka cyclone caused $4.1 bn damage: World Bank
-
Billionaire Ellison offers personal guarantee for son's bid for Warner Bros
-
Tech stocks lead Wall Street higher, gold hits fresh record
-
Telefonica to shed around 5,500 jobs in Spain
-
McCullum wants to stay as England coach despite Ashes drubbing
-
EU slams China dairy duties as 'unjustified'
-
Italy fines Apple nearly 100 mn euros over app privacy feature
-
America's Cup switches to two-year cycle
-
Jesus could start for Arsenal in League Cup, says Arteta
-
EU to probe Czech aid for two nuclear units
-
Strauss says sacking Stokes and McCullum will not solve England's Ashes woes
-
Noel takes narrow lead after Alta Badia slalom first run
-
Stocks diverge as rate hopes rise, AI fears ease
-
Man City players face Christmas weigh-in as Guardiola issues 'fatty' warning
-
German Christmas markets hit by flood of fake news
-
Liverpool fear Isak has broken leg: reports
-
West Indies captain says he 'let the team down' in New Zealand Tests
-
Thailand says Cambodia agrees to border talks after ASEAN meet
-
Alleged Bondi shooters conducted 'tactical' training in countryside, Australian police say
-
Swiss court to hear landmark climate case against cement giant
-
Knicks' Brunson scores 47, Bulls edge Hawks epic
-
Global nuclear arms control under pressure in 2026
Massachusetts Cannabis Contamination Crisis Exposes Federal Negligence While DEA Targets Science, Not Safety
Where Is the DEA? The Real Threat Isn't Research-It's Rotten Weed.
"This is the height of hypocrisy," said Duane Boise, CEO MMJ. "DEA bureaucrats are blocking clean cannabis grown in a DEA inspected cultivation facility, while contaminated products circulate freely under their watch. The agency has abandoned its duty to protect patients."
WASHINGTON, DC / ACCESS Newswire / August 7, 2025 / While the Massachusetts Cannabis Control Commission scrambles to contain a major public health scandal involving 544 contaminated marijuana samples, Thomas Prevoznik and the Drug Enforcement Administration (DEA)-the agency that claims to "protect public health and safety from the dangers of drugs"-is nowhere to be found.

According to a Public Health and Safety Advisory issued today by the Massachusetts Commission, contaminated and potentially contaminated marijuana products were sold throughout the state between April 1, 2024, and April 15, 2025. The issue? The products failed Total Yeast and Mold testing -a serious risk to patients and consumers, especially those who are immunocompromised. Yet this failure of regulatory oversight occurred right under DEA's nose, in a federally illegal marketplace they claim to police.
So, we ask again: Where is the DEA?
Moldy Marijuana, Real Harm
Massachusetts authorities have confirmed that hundreds of samples tested positive for contaminants but were somehow allowed to enter commercial circulation. This isn't about labeling violations or clerical errors-it's about inhaled mold, a known trigger for respiratory infections, allergic reactions, and even long-term lung damage.
The contaminated products were tracked using Metrc, a seed-to-sale traceability system required by law. The system worked. But what failed? Federal oversight, accountability, and DEA enforcement.
DEA Targets Science, Not Safety
While moldy weed was being sold to unsuspecting patients, what was the DEA doing?
Blocking MMJ BioPharma Cultivation from producing pharmaceutical grade cannabis for FDA approved clinical trials.
Sabotaging medical marijuana research with unconstitutional Administrative Law Judge (ALJ) proceedings.
Wasting time litigating against compliant, registered entities seeking to cure Huntington's Disease and Multiple Sclerosis.
Upholding a hypocritical regime where unregulated street level weed flourishes, while federally compliant applicants like MMJ BioPharma Cultrivation are stonewalled for trying to protect patients and follow science.
Let's be clear: the DEA is not protecting public health. It's obstructing it.
The Real Threat Isn't Research-It's Rotten Weed
The DEA's warped priorities are now a matter of public danger. Instead of helping to build a controlled, pharmaceutical-grade cannabis pipeline, the agency enables a fragmented, state-by-state chaos where contaminated products slip through the cracks and patients pay the price.
Ironically, the same agency that refuses to allow MMJ to grow clean, pharmaceutical cannabis in a DEA inspected facility also looks the other way as moldy, hazardous marijuana circulates in retail dispensaries.
MMJ BioPharma: Compliant, Blocked, and Ignored
MMJ BioPharma has:
secured a DEA analytical lab registration since 2022.
Submitted applications to manufacture and grow cannabis under Schedule I for FDA clinical trials.
Secured Orphan Drug Designation from the FDA for two devastating conditions.
And yet- after seven years -no federal approval.
A Simple Question for Administrator Terry Cole
Now that the Senate has confirmed Terry Cole as DEA Administrator, the public deserves an answer:
Will you keep blocking clean, FDA-regulated cannabis research while patients unknowingly inhale moldy weed from state markets you refuse to regulate?
The answer to that question will define not only your legacy-but whether the DEA finally chooses science over sabotage.
Final Thoughts
The DEA says it exists to fight drug abuse and protect public health. But in the face of real harm- contaminated marijuana entering legal markets -it's missing in action.
It's time for a new era of leadership. One where medical science leads, and moldy lies die.
The time for excuses is over. The time for action is now.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-85832
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
A.Mahlangu--AMWN